Skip to main content

Long-term Microphysiological Sample Imaging for Evaluation of Polypharmacy in Liver

Objective

DeLIVERY aims to build a radically new technology for personalized health care, which provides, for the first time, the possibility to investigate polypharmacy on individual patients. Polypharmacy is the effect that the many combinations and permutations of drug mixtures which are typically prescribed to the chronically sick or the elderly population (e.g. painkillers, beta blockers, blood thinners, anti-depressants, and statins) have on the human body. Polypharmacy is becoming a major issue in the ageing population, as well over 10% of hospital admissions for people over 60 years of age are due to currently unknown interactions of the multiple drugs being prescribed by the specialized physicians and general practitioners routinely visited by the elderly. Currently, no single platform exists that can be utilized in a highly parallelized fashion to monitor such effects at the cellular and tissue level. DeLIVERY will provide an integrated microphysiological system (MPS) culture and microscopic imaging platform specifically for the purpose of maintaining, treating and long-term imaging of patient-specific cells within their microenvironment. This MPS platform will allow physicians, biomedical scientists, and researchers to determine the individual response of human tissue biopsies to a combination of multiple drugs. DeLIVERY will enable individualized treatment options providing essential tools towards a better quality of life for older people by allowing improved personalized healthcare. Novel medicines with the potential to reverse the effects of ageing and non-alcoholic fatty liver disease (NAFLD) will be tested within typical polypharmacy contexts to determine possible interactions, and the DeLIVERY MPS system will be the purpose-built platform to provide this service. Such a system also requires a paradigm shift in microscopy - away from the single, bulky instrument providing one imaging modality towards compact and modular, yet still high-end, devices.

Coordinator

UNIVERSITAET BIELEFELD
Net EU contribution
€ 558 190,00
Address
Universitaetsstrasse 25
33615 Bielefeld
Germany

See on map

Region
Nordrhein-Westfalen Detmold Bielefeld, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Participants (5)

UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET
Norway
Net EU contribution
€ 568 009,00
Address
Hansine Hansens Veg 14
9019 Tromso

See on map

Region
Norge Nord-Norge Troms og Finnmark
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
VRIJE UNIVERSITEIT BRUSSEL
Belgium
Net EU contribution
€ 430 595,00
Address
Pleinlaan 2
1050 Brussel

See on map

Region
Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
EVANGELISCHES KLINIKUM BETHEL GGMBH
Germany
Net EU contribution
€ 358 955,00
Address
Kantensiek 11
33617 Bielefeld

See on map

Region
Nordrhein-Westfalen Detmold Bielefeld, Kreisfreie Stadt
Activity type
Research Organisations
Non-EU contribution
€ 0,00
EXCELITAS PCO GMBH
Germany
Net EU contribution
€ 213 750,00
Address
Donaupark 11
93309 Kelheim

See on map

Region
Bayern Niederbayern Kelheim
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
CHERRY BIOTECH
France
Net EU contribution
€ 870 430,00
Address
2eme Etage, Halls A-b Et C14 Rue De La Beaune
93100 Montreuil

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ile-de-France Ile-de-France Seine-Saint-Denis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00